# A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

> **NCT02861014** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 681 (actual)

## Conditions studied

- Multiple Sclerosis, Relapsing-Remitting

## Interventions

- **BIOLOGICAL:** Ocrelizumab

## Key facts

- **NCT ID:** NCT02861014
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-09
- **Primary completion:** 2019-10-25
- **Final completion:** 2020-12-15
- **Target enrollment:** 681 (ACTUAL)
- **Last updated:** 2022-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02861014

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02861014, "A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02861014. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*